中枢神経(CNS)刺激薬の世界市場2019-2023

◆英語タイトル:Global Central Nervous System (CNS) Stimulant Drugs Market 2019-2023
◆商品コード: IRTNTR31693
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年7月20日
◆ページ数:121
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:アジア、ヨーロッパ、北米、その他
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Technavio社の本調査レポートでは、中枢神経(CNS)刺激薬の世界市場について調べ、中枢神経(CNS)刺激薬の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、中枢神経(CNS)刺激薬の市場規模をセグメンテーション別(用途別(注意欠陥多動性障害、ナルコレプシー、その他)、)と地域別(アジア、ヨーロッパ、北米、その他)に分けて算出しました。Technavio社は中枢神経(CNS)刺激薬の世界市場規模が2019-2023期間中に年平均5%成長すると予測しています。
・サマリー
・レポートの範囲
・中枢神経(CNS)刺激薬の市場状況
・中枢神経(CNS)刺激薬の市場規模
・中枢神経(CNS)刺激薬の市場予測
・中枢神経(CNS)刺激薬の世界環境:ファイブフォース分析
・市場セグメンテーション:用途別(注意欠陥多動性障害、ナルコレプシー、その他)
・中枢神経(CNS)刺激薬の顧客状況
・主要地域別市場規模:アジア、ヨーロッパ、北米、その他
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Central Nervous System (CNS) Stimulant Drugs Market: About this market

Central nervous system stimulant drugs are primarily used to treat CNS disorders. These stimulants act by increasing the dopamine level in the brain, which increases the blood pressure and heart rate. Technavio’s central nervous system stimulant drugs market analysis considers sales from attention-deficit hyperactivity disorder, narcolepsy, and others. Our analysis also considers the sales of central nervous system stimulant drugs in Asia, Europe, North America, and ROW. In 2018, the attention-deficit hyperactivity disorder segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the increasing prevalence of this disorder among children and adolescents, easy availability of stimulants will play a significant role in the attention-deficit hyperactivity disorder segment to maintain its market position. Also, our global central nervous system stimulant drugs market report also looks at factors such as rise in CNS disorders, approval of new stimulants, and increasing use of stimulants worldwide. However, numerous side effects of drugs, development of the first-in-class therapeutics, and increasing demand for non-pharmacological therapies may hamper the growth of the central nervous system stimulant drugs industry over the forecast period.

Global Central Nervous System (CNS) Stimulant Drugs Market: Overview

The rise in CNS disorders

CNS disorders such as sleep apnea, narcolepsy, and attention-deficit hyperactivity disorder have witnessed a significant rise in recent years. Attention-deficit hyperactivity disorder interferes with the functioning and development of a person. This increasing prevalence of CNS disorders will lead to the expansion of the global central nervous system stimulant drugs market at a CAGR of over 5% during the forecast period.

Rising demand to legalize cannabis worldwide

Cannabis can increase the dopamine level in the brain and is used widely in the treatment of attention-deficit hyperactivity disorder. According to researcher’s synthetic cannabis may have benefits on people with sleep apnea due to the modulatory effects of these drugs on serotonin-mediated apneas. This demand to legalize cannabis across the world is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global central nervous system stimulant drugs market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of a few major players, the global central nervous system stimulant drugs market is concentrated. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several central nervous system stimulant drugs manufacturers, that include GlaxoSmithKline Plc, Johnson & Johnson Services Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd.

Also, the central nervous system stimulant drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY APPLICATION

Market segmentation by application

Comparison by application

Attention-deficit hyperactivity disorder – Market size and forecast

2018-2023

Narcolepsy – Market size and forecast 2018-2023

Others – Market size and forecast 2018-2023

Market opportunity by application

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

R&D of stimulants to treat attention-deficit hyperactivity disorder

Rising demand to legalize cannabis worldwide

Increasing repurposing of drugs

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

GlaxoSmithKline Plc

Johnson & Johnson Services Inc.

Novartis AG

Pfizer Inc.

Teva Pharmaceutical Industries Ltd.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Global central nervous system (CNS) disorders drugs market

Exhibit 02: Segments of global central nervous system (CNS) disorders drugs market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Product overview

Exhibit 06: Market definition – Inclusions and exclusions checklist

Exhibit 07: Market size 2018

Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 10: Five forces analysis 2018

Exhibit 11: Five forces analysis 2023

Exhibit 12: Bargaining power of buyers

Exhibit 13: Bargaining power of suppliers

Exhibit 14: Threat of new entrants

Exhibit 15: Threat of substitutes

Exhibit 16: Threat of rivalry

Exhibit 17: Market condition – Five forces 2018

Exhibit 18: Application – Market share 2018-2023 (%)

Exhibit 19: Comparison by application

Exhibit 20: Attention-deficit hyperactivity disorder – Market size and forecast 2018-2023 ($ millions)

Exhibit 21: Attention-deficit hyperactivity disorder – Year-over-year growth 2019-2023 (%)

Exhibit 22: Narcolepsy – Market size and forecast 2018-2023 ($ millions)

Exhibit 23: Narcolepsy – Year-over-year growth 2019-2023 (%)

Exhibit 24: Others – Market size and forecast 2018-2023 ($ millions)

Exhibit 25: Others – Year-over-year growth 2019-2023 (%)

Exhibit 26: Market opportunity by application

Exhibit 27: Customer landscape

Exhibit 28: Market share by geography 2018-2023 (%)

Exhibit 29: Geographic comparison

Exhibit 30: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 31: North America – Year-over-year growth 2019-2023 (%)

Exhibit 32: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 33: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 34: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 35: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 36: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 37: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 38: Key leading countries

Exhibit 39: Market opportunity

Exhibit 40: Impact of drivers and challenges

Exhibit 41: Vendor landscape

Exhibit 42: Landscape disruption

Exhibit 43: Vendors covered

Exhibit 44: Vendor classification

Exhibit 45: Market positioning of vendors

Exhibit 46: GlaxoSmithKline Plc – Vendor overview

Exhibit 47: GlaxoSmithKline Plc – Business segments

Exhibit 48: GlaxoSmithKline Plc – Organizational developments

Exhibit 49: GlaxoSmithKline Plc – Geographic focus

Exhibit 50: GlaxoSmithKline Plc – Segment focus

Exhibit 51: GlaxoSmithKline Plc – Key offerings

Exhibit 52: Johnson & Johnson Services Inc. – Vendor overview

Exhibit 53: Johnson & Johnson Services Inc. – Business segments

Exhibit 54: Johnson & Johnson Services Inc. – Organizational developments

Exhibit 55: Johnson & Johnson Services Inc. – Geographic focus

Exhibit 56: Johnson & Johnson Services Inc. – Segment focus

Exhibit 57: Johnson & Johnson Services Inc. – Key offerings

Exhibit 58: Novartis AG – Vendor overview

Exhibit 59: Novartis AG – Business segments

Exhibit 60: Novartis AG – Organizational developments

Exhibit 61: Novartis AG – Geographic focus

Exhibit 62: Novartis AG – Segment focus

Exhibit 63: Novartis AG – Key offerings

Exhibit 64: Pfizer Inc. – Vendor overview

Exhibit 65: Pfizer Inc. – Business segments

Exhibit 66: Pfizer Inc. – Organizational developments

Exhibit 67: Pfizer Inc. – Geographic focus

Exhibit 68: Pfizer Inc. – Segment focus

Exhibit 69: Pfizer Inc. – Key offerings

Exhibit 70: Teva Pharmaceutical Industries Ltd. – Vendor overview

Exhibit 71: Teva Pharmaceutical Industries Ltd. – Business segments

Exhibit 72: Teva Pharmaceutical Industries Ltd. – Organizational developments

Exhibit 73: Teva Pharmaceutical Industries Ltd. – Segment focus

Exhibit 74: Teva Pharmaceutical Industries Ltd. – Key offerings

Exhibit 75: Validation techniques employed for market sizing

Exhibit 76: Definition of market positioning of vendors



【掲載企業】

GlaxoSmithKline Plc, Johnson & Johnson Services Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[中枢神経(CNS)刺激薬の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆